Post-mortem restorations in ancient Egyptian animal mummies using imaging

Animal mummy bundles in museum collections are evaluated through the application of imaging and are categorised as true, those containing skeletal remains, and pseudo, those containing non-skeletal remains. True mummies exhibited a variety of compositions, and frequently contained less than one complete individual despite the external appearance; an explanation for which has been ancient forgery. The analysis of animal mummy bundles in the Ancient Egyptian Animal Bio Bank, University of Manchester, suggested that in some instances this explanation may be inaccurate. This paper discusses nine mummy bundles, which displayed a variety of post-mortem modifications interpreted in two ways: the necessity for physical completion and the concept of the mummy bundle (rather than the content) as the primary representation of the deceased

Diversity and structure of Bettongia tropica: using population genetics to guide reintroduction and help prevent the extinction of an endangered Australian marsupial

Conservation translocations can restore populations and prevent extinction of threatened species. Sourcing adequate genetic diversity is an essential consideration when planning reintroductions, because it influences individual fitness and long-term persistence of populations, yet available populations of threatened species may lack diversity. We estimated population genetic parameters for one of Australia’s most threatened mammals, the northern bettong, Bettongia tropica, to select source populations for reintroduction. Individuals from sites across the species’ extant range in the Wet Tropics of north Queensland were genotyped, using 6,133 informative SNPs. We found that samples clustered into four populations: an isolated northern population at Mt Spurgeon and three connected southern populations in the Lamb Range. Most of the species’ genetic diversity was dispersed across the Lamb Range populations in approximately equal proportions. Populations showed an isolation-by-distance effect, even over short distances within continuous habitat. Admixture of populations was high at distances 11 km, and there was asymmetrical gene flow between the two closest neighboring populations. All populations had small effective sizes and experienced drift, but connectivity appears to have mitigated drift and stabilized population sizes within the Lamb Range. The Mt Spurgeon population had a very small effective population size and low genetic diversity. We use our findings to weigh up the risks and benefits of mixing sources for reintroduction, and we recommend a mixed source approach. We do not currently recommend sourcing individuals from Mt Spurgeon and conservation efforts to preserve this population are urgently required

Organic residue analysis of Egyptian votive mummies and their research potential

YesVast numbers of votive mummies were produced in Egypt during the Late Pharaonic, Ptolemaic, and Roman periods. Although millions remain in situ, many were removed and have ultimately entered museum collections around the world. There they have often languished as uncomfortable reminders of antiquarian practices with little information available to enhance their value as artefacts worthy of conservation or display. A multi-disciplinary research project, based at the University of Manchester, is currently redressing these issues. One recent aspect of this work has been the characterization of natural products employed in the mummification of votive bundles. Using gas chromatography–mass spectrometry and the well-established biomarker approach, analysis of 24 samples from 17 mummy bundles has demonstrated the presence of oils/fats, natural waxes, petroleum products, resinous exudates, and essential oils. These results confirm the range of organic materials employed in embalming and augment our understanding of the treatment of votives. In this first systematic initiative of its kind, initial findings point to possible trends in body treatment practices in relation to chronology, geography, and changes in ideology which will be investigated as the study progresses. Detailed knowledge of the substances used on individual bundles has also served to enhance their value as display items and aid in their conservation.RCB is supported by a PhD studentship from the Art and Humanities Research Council (43019R00209). L.M. and S.A.W. are supported by a Leverhulme Trust Research Project Award (RPG-2013-143)

The impact of supported telemetric monitoring in people with type 2 diabetes: study protocol for a randomised controlled trial

BackgroundDiabetes prevalence is increasing and current methods of management are unsustainable. Effective approaches to supporting self-management are required. The aim of this randomized controlled trial is to establish whether supported telemetric monitoring of glycemic control and blood pressure results in reductions in glycosylated hemoglobin (HbA1c; the primary outcome of a measure of long-term glycemic control) and secondary outcomes of blood pressure and weight among people with poorly controlled diabetes compared to a control group receiving usual care.Methods/DesignDesign: multi-center, randomized controlled trial with embedded qualitative study.Setting: primary care in Lothian, Kent, Glasgow and Borders regions in the UK.Participants: people with type 2 diabetes and confirmed HbA1c >7.5% (58 mmol/mol).Intervention/comparison: randomization to intervention or control groups will be performed by the Edinburgh Clinical Trials Unit. Participants in the intervention group will be shown how to use blood glucose and blood pressure monitors and weighing scales which use Bluetooth wireless technology to transmit readings via modem to a remote server. These participants will be asked to provide at least twice weekly measurements of morning and evening blood glucose and weekly measurements of weight and blood pressure. Measurements will be checked at least weekly by practice nurses who will contact the patients to adjust therapy according to guidelines and reinforce lifestyle advice. Participants in the control group will receive usual care. All participants will receive an individual education session.ollow-up: measurements will be performed at practices 9 months after randomization by research nurses blinded to allocation. The primary outcome measure is HbA1c and secondary outcomes measure are daytime systolic and diastolic blood pressure, weight and cost per quality-adjusted life year.Analysis: intention-to-treat analyses will be performed. The sample size of 320 participants allows for 20% drop-out and has 80% power at 5% significance to detect a 0.5% absolute (6 mmol/mol) fall in HbA1c in the intervention group. The qualitative study will explore the experiences of patients and professionals using the intervention

Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes:External Validation Using Data From the National Scottish Diabetes Register

Objective: To evaluate the performance of five cardiovascular disease (CVD) risk scores developed in diabetes populations and compare their performance to QRISK2. Research Design and Methods: A cohort of people diagnosed with type 2 diabetes between 2004 and 2016 was identified from the Scottish national diabetes register. CVD events were identified using linked hospital and death records. Five-year risk of CVD was estimated using each of QRISK2, ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation), Cardiovascular Health Study (CHS), New Zealand Diabetes Cohort Study (NZ DCS), Fremantle Diabetes Study, and Swedish National Diabetes Register (NDR) risk scores. Discrimination and calibration were assessed using the Harrell C statistic and calibration plots, respectively. Results: The external validation cohort consisted of 181,399 people with type 2 diabetes and no history of CVD. There were 14,081 incident CVD events within 5 years of follow-up. The 5-year observed risk of CVD was 9.7% (95% CI 9.6, 9.9). C statistics varied between 0.66 and 0.67 for all risk scores. QRISK2 overestimated risk, classifying 87% to be at high risk for developing CVD within 5 years; ADVANCE underestimated risk, and the Swedish NDR risk score calibrated well to observed risk. Conclusions: None of the risk scores performed well among people with newly diagnosed type 2 diabetes. Using these risk scores to predict 5-year CVD risk in this population may not be appropriate

Host Plants and Climate Structure Habitat Associations of the Western Monarch Butterfly

The monarch butterfly is one of the most easily recognized and frequently studied insects in the world, and has recently come into the spotlight of public attention and conservation concern because of declining numbers of individuals associated with both the eastern and western migrations. Historically, the larger eastern migration has received the most scientific attention, but this has been changing in recent years, and here we report the largest-ever attempt to map and characterize non-overwintering habitat for the western monarch butterfly. Across the environmentally and topographically complex western landscape, we include 8,427 observations of adults and juvenile monarchs, as well as 20,696 records from 13 milkweed host plant species. We find high heterogeneity of suitable habitats across the geographic range, with extensive concentrations in the California floristic province in particular. We also find habitat suitability for the butterfly to be structured primarily by host plant habitat associations, which are in turn structured by a diverse suite of climatic variables. These results add to our knowledge of range and occupancy determinants for migratory species and provide a tool that can be used by conservation biologists and researchers interested in interactions among climate, hosts and host-specific animals, and by managers for prioritizing future conservation actions at regional to watershed scales

Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013

No abstract available

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma

Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy. In this study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line STSA-1 and the analysis of the virus-mediated oncolytic and immunological effects of two different Lister VACV LIVP1.1.1 and GLV-1h68 strains against CSTS. Cell culture data demonstrated that both tested VACV strains efficiently infected and destroyed cells of the canine soft tissue sarcoma line STSA-1. In addition, in our new canine sarcoma tumor xenograft mouse model, systemic administration of LIVP1.1.1 or GLV-1h68 viruses led to significant inhibition of tumor growth compared to control mice. Furthermore, LIVP1.1.1 mediated therapy resulted in almost complete tumor regression and resulted in long-term survival of sarcoma-bearing mice. The replication of the tested VACV strains in tumor tissues led to strong oncolytic effects accompanied by an intense intratumoral infiltration of host immune cells, mainly neutrophils. These findings suggest that the direct viral oncolysis of tumor cells and the virus-dependent activation of tumor-associated host immune cells could be crucial parts of anti-tumor mechanism in STSA-1 xenografts. In summary, the data showed that both tested vaccinia virus strains and especially LIVP1.1.1 have great potential for effective treatment of CSTS

SLC35A2â CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals

Pathogenic de novo variants in the Xâ linked gene SLC35A2 encoding the major Golgiâ localized UDPâ galactose transporter required for proper protein and lipid glycosylation cause a rare type of congenital disorder of glycosylation known as SLC35A2â congenital disorders of glycosylation (CDG; formerly CDGâ IIm). To date, 29 unique de novo variants from 32 unrelated individuals have been described in the literature. The majority of affected individuals are primarily characterized by varying degrees of neurological impairments with or without skeletal abnormalities. Surprisingly, most affected individuals do not show abnormalities in serum transferrin Nâ glycosylation, a common biomarker for most types of CDG. Here we present data characterizing 30 individuals and add 26 new variants, the single largest study involving SLC35A2â CDG. The great majority of these individuals had normal transferrin glycosylation. In addition, expanding the molecular and clinical spectrum of this rare disorder, we developed a robust and reliable biochemical assay to assess SLC35A2â dependent UDPâ galactose transport activity in primary fibroblasts. Finally, we show that transport activity is directly correlated to the ratio of wildâ type to mutant alleles in fibroblasts from affected individuals.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/150498/1/humu23731_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/150498/2/humu23731-sup-0001-Supp_Mat__2019.2.10_.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/150498/3/humu23731.pd